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Abstract
Background: Office-based workers typically spend 70–85% of working hours, and a large proportion of leisure time,
sitting. High levels of sitting have been linked to poor health. There is a need for fully powered randomised
controlled trials (RCTs) with long-term follow-up to test the effectiveness of interventions to reduce sitting. This
paper describes the methodology of a three-arm cluster RCT designed to determine the effectiveness and cost-
effectiveness of the SMART Work & Life intervention, delivered with and without a height-adjustable desk, for
reducing daily sitting.
Methods/design: A three-arm cluster RCT of 33 clusters (660 council workers) will be conducted in three areas in
England (Leicester; Manchester; Liverpool). Office groups (clusters) will be randomised to the SMART Work & Life
intervention delivered with (group 1) or without (group 2) a height-adjustable desk or a control group (group 3).
SMART Work & Life includes organisational (e.g., management buy-in, provision/support for standing meetings),
environmental (e.g., relocating waste bins, printers), and group/individual (education, action planning, goal setting,
addressing barriers, coaching, self-monitoring, social support) level behaviour change strategies, with strategies
driven by workplace champions. Baseline, 3, 12 and 24 month measures will be taken. Primary outcome: Objectively
measured daily sitting time (activPAL3). Secondary outcomes: objectively measured sitting, standing, stepping,
prolonged sitting and moderate-to-vigorous physical activity time and number of steps at work and daily;
objectively measured sleep (wrist accelerometry). Adiposity, blood pressure, fasting glucose, glycated haemoglobin,
cholesterol (total, HDL, LDL) and triglycerides will be assessed from capillary blood samples. Questionnaires will
examine dietary intake, fatigue, musculoskeletal issues, job performance and satisfaction, work engagement,
occupational and general fatigue, stress, presenteeism, anxiety and depression and sickness absence (organisational
records). Quality of life and resources used (e.g. GP visits, outpatient attendances) will also be assessed. We will
conduct a full process evaluation and cost-effectiveness analysis.
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Discussion: The results of this RCT will 1) help to understand how effective an important simple, yet
relatively expensive environmental change is for reducing sitting, 2) provide evidence on changing behaviour
across all waking hours, and 3) provide evidence for policy guidelines around population and workplace
health and well-being.
Trial registration: ISRCTN11618007. Registered on 21 January 2018.
Keywords: Behaviour change, Sit-stand, Workplace, activPAL, Standing
Background
Technological innovations and economic advances have
led to increases in physical inactivity and sedentary behav-
iour [1]. Evidence indicates that it is not only important to
be physically active for at least 150 min a week, but also to
limit the number of waking hours spent being sedentary
(i.e., sitting). A wealth of epidemiological evidence now
exists that demonstrates that sedentary behaviour is asso-
ciated with an increased risk of poor metabolic health [2]
and chronic disease (type 2 diabetes, cardiovascular dis-
ease, some cancers and mortality) [3–6], often independ-
ently of BMI and physical activity.
Office workers are one of the most sedentary popula-
tions, with data showing that they spend 70–85% of time
at work sitting, with over a third of total sitting time being
accumulated in bouts of prolonged, unbroken sitting of
30 min or more [7]. Additionally, research has shown that
workers who spend large proportions of their time sitting
at work also spend more time sitting during leisure time
than their less sedentary counterparts [8]. A small number
of epidemiological studies using isotemporal substitution
analysis have shown that substituting sitting time for
standing and stepping was beneficially associated with
markers of cardiometabolic health such as glucose, insulin,
and inflammation [9–11]. Furthermore, a rapidly growing
body of acute experimental evidence demonstrates that
avoiding long bouts of sitting by incorporating short (e.g.,
2–5 min) but frequent (e.g., every 20-30 min) bouts of
more light intensity movement (standing and stepping)
improves glucose, insulin, blood pressure and fatigue
levels [12–18]. Such sitting reduction strategies have also
been shown to reduce musculoskeletal (e.g., low back) dis-
comfort in office workers [19].
Recent evidence suggests that high levels of
moderate-to-vigorous physical activity (MVPA), for ex-
ample at least 60–120 min per day, may offset the in-
creased mortality risks associated with high levels of total
sitting time (> 8 h/day) [20, 21]. However, the high levels of
activity needed to be protective are unlikely to be achiev-
able for most of the population. Indeed, a recent study of
one million adults showed that 75% do not undertake this
amount of MVPA [21]. Therefore, a first “behavioural” step
could be to simply get people standing and moving more
frequently as part of their day.
A review was published in 2016, and updated in 2018,
summarising the effectiveness of workplace interventions
for reducing sitting time at work [22, 23]. These interven-
tions included physical workplace changes such as provid-
ing height adjustable desks to enable sitting or standing at
work, pedalling workstations and treadmill desks, policy
changes, information provision and counselling, and com-
puter prompts. Providing height-adjustable workstations
was the most frequently implemented intervention and
was reported as the most promising for reducing sitting
time at work (average reduction of 100 min/work day in
the short term, 57 min/work day in the medium term)
[23]. Whilst positive findings were observed, the review
concluded that the quality of evidence was low to very low
for most studies mainly because studies were poorly de-
signed; for example, there was a lack of non-biased cluster
randomised controlled trials, and generally small samples.
They also concluded that ‘there is a need for larger
cluster-randomised trials with longer term follow-up’.
To date only a handful of studies currently address
these limitations [24, 25] and only one ongoing study, al-
beit that does not include a control group, has a follow
up beyond 12 months [26]. The Stand More AT Work
(SMArT Work) multi-component intervention was eval-
uated through a large cluster RCT with follow up at 3, 6
and 12 months [24, 27]. Although SMArT Work was
successful in reducing sitting time at work et all follow
up time points, results suggested that no changes in sit-
ting outside of work were made as reductions seen for
daily sitting time were similar to those observed during
work hours [27]. Similarly, the Stand Up Victoria trial
also observed significant changes in sitting time across
the day, but findings suggested that this was also pre-
dominantly driven by workplace changes, rather than
changes during non-work time [28]. To maximise the
potential health benefits of reducing sitting time there is
a need for interventions to take a ‘whole of day’ ap-
proach to behaviour change, and focus not only on
workplace sitting time, but also on sitting outside of
work.
In recent years, interventions focused on reducing sit-
ting time in the workplace have involved providing the
employee with a height-adjustable workstation to enable
them to sit or stand to perform their work tasks. As
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mentioned previously, evidence indicates that this type of
intervention shows promise for helping employees to re-
duce their sitting time [22, 23]. However, this piece of
equipment is relatively expensive. Moreover, while the re-
cent systematic review of workplace interventions sug-
gests that greater reductions in sitting are seen with
interventions involving height-adjustable workstations in
comparison to interventions that do not (e.g., information
provision and counselling), a direct comparison of a sitting
reduction intervention with and without the provision of a
height-adjustable workstation has not been conducted
within a single, large, robustly designed study. This is an
important next step as it will allow researchers and em-
ployers to understand the importance of providing a sim-
ple, but relatively expensive environmental change for
significant reductions in sitting. One active research trial
in the US is evaluating the efficacy of a multilevel inter-
vention with (STAND +) and without (MOVE +) the
provision of sit-stand workstations and although a large
randomised trial, it does not include a control group [26].
Aims and objectives of the study
Aim
The aim of this study is to determine the long-term effect-
iveness and cost-effectiveness of the multi-component
SMART Work & Life intervention (when provided with
and without a height-adjustable workstation) for reducing
daily sitting time in office workers compared with no
intervention. If both interventions are shown to be effect-
ive, a secondary aim will be to determine if one interven-
tion is more effective than the other. SMART Work &
Life is a refined and extended version of the previously
evaluated SMArT Work intervention [24, 27].
Primary objective
To investigate the impact of SMART Work & Life, deliv-
ered with and without a height adjustable workstation,
on objectively measured daily sitting time compared to
usual practice at 24-months follow-up.
Secondary objectives
To investigate the impact of SMART Work & Life, deliv-
ered with and without a height adjustable workstation, over
the short (assessed at 3 months), medium (assessed at
12 months) and longer term (assessed at 24 months) on;
 daily sitting time (3 and 12 months)
 sitting time during working hours
 daily prolonged sitting time and inside/outside of
working hours
 daily standing time and inside/outside of working
hours
 daily light and moderate-to-vigorous physical activ-
ity and inside/outside of working hours
 daily stepping time and number of steps and inside/
outside of working hours
 adiposity (BMI, percent body fat, waist
circumference)
 blood pressure
 blood markers (e.g. blood glucose, cholesterol,
triglycerides)
 musculoskeletal issues
 psychosocial variables (e.g. fatigue, stress, anxiety
and depression, work engagement, job performance
and satisfaction, presenteeism, sickness absence, and
quality of life)
 sleep
We will also conduct a full process evaluation and a
full economic evaluation.
Methods
Design and randomisation
This is a three-arm cluster randomised controlled trial
(RCT) aiming to recruit 33 clusters. Clusters will be ran-
domised at the office level to reduce the risk of contam-
ination. Using computer generated lists, office groups
(clusters) will be randomised by a statistician from the
Leicester Clinical Trials Unit to one of the three groups,
stratified by Council area (e.g., Leicester) and cluster size
(< 10 participants, ≥10 participants). Randomisation will
be performed in batches after clusters have completed
their baseline measures. The clusters will be recruited
from Councils within the Leicester, Manchester and Liv-
erpool areas in the UK. We aim to recruit 660 office
workers across the 33 clusters. Clusters will be rando-
mised to receive one of the following conditions: 1) The
multi-component SMART Work & Life intervention
with a height-adjustable workstation (intervention 1), or
2) The multi-component SMART Work & Life interven-
tion without a height-adjustable workstation (interven-
tion 2) or 3) usual practice (control condition).
Measurements will be repeated, using identical standar-
dised procedures, at 3 months to assess any short-term
changes and 12 months and 24-months to assess any
longer term changes. Observations, questionnaires and
focus groups with office workers and workplace cham-
pions will be conducted throughout the intervention
period as part of our full process evaluation. This study
will be conducted, analysed and reported according to
the Consolidation Standards of Reporting Trials (CON-
SORT) statement for cluster RCTs. Given the nature of
the study it is not possible to blind the participants to
which intervention they receive. Measurement team
members, apart from the team lead, were blinded to
group randomisation. Ethical approval has been sought
and obtained from the University of Leicester’s College
of Life Sciences and University of Salford’s Research,
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Enterprise and Engagement Ethical Approval Panel. The
University of Leicester will act as study sponsor. Figure 1
shows the overall study design.
Setting
This study is targeting office workers within City and
Borough Councils within the Leicester, Manchester and
Liverpool areas, UK.
Cluster and participant recruitment
The study will be advertised in several ways (these have
been informed by Councils themselves):
 Using the councils’ weekly newsletter
 Using the councils’ intranet
 Through Manager meetings
 Displaying posters on display boards
 Through more targeted strategies directly to
appropriate office-based departments e.g., office walk
arounds
It will be made clear in the study adverts that the
study is looking to recruit office-based employees who
spend the majority of their work and waking day sitting
down (see inclusion criteria) and that the study will be
looking to recruit as many employees within the same
office space as possible. Employees who want to hear
more about the study will be invited to a presentation
where the study will be explained. At the end of the
presentation participant information sheets and reply
Fig. 1 Study design
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slips (which will include a pre-screening questionnaire
to gather basic information to assess eligibility) will be
given out to employees who are interested in taking part.
The study team’s contact details will also be provided on
all study recruitment material so that interested em-
ployees can request a participant information sheet dir-
ectly from the research team.
Inclusion and exclusion criteria
Participants who meet the following criteria will be
eligible:
 Spend the majority of their day sitting (> 50%). This
will initially be self-reported and be used as screen-
ing criteria prior to the consent and baseline meas-
urement visit. This will subsequently be confirmed
using the objective data collected via the activPAL
device (see measures section).
 Work for the council at least 60% full time
equivalent.
 Work in the same office at least 3 days per week.
 Be willing and able to give informed consent to take
part in the study.
 Able to walk without the use of an assistive device
or requiring assistance from another person.
The participant may not enter the study if any of the
following apply:
 They are currently pregnant.
 Currently using a height-adjustable workstation at
their primary work location.
 Unable to communicate in English.
 Unable to provide written informed consent.
Sample size
The primary analysis will be performed using linear
multilevel models, which require a minimum of 10 clus-
ters per arm in order to robustly estimate random effects
[29]. Power calculations indicated that with a sample
size of 10 clusters per arm and an average cluster size of
14, this study would have over 90% power to detect a
60 min reduction in overall sitting time with a two-tailed
significance level of 5%. The calculations assumed a
standard deviation of 90 min (informed by SMArT
Work, [27]), a conservative intraclass correlation coeffi-
cient (ICC) of 0.05 (informed by Stand Up Victoria,
[28]), a coefficient of variation to allow for variation in
cluster size of 0.54. These calculations allowed for mul-
tiple comparisons against the control group. The number
of clusters per arm has been inflated by 1 to allow for
whole cluster drop out and the sample size was also in-
flated by 30% to allow for potential individual loss to
follow-up and non-compliance with the primary outcome
(inflating the n per cluster from 14 to 20). This gives a
total sample size of 660 to be recruited, with 11 clusters
per arm. Finally, the sensitivity of power was assessed
against alternative ICC values of 0.021 and 0.10 [28]. Ad-
equate power for RCTs is widely accepted as 80%, and
with these ICC values the power was above the required
level at 98 and 81%, respectively.
Intervention conditions
Background
The SMART Work & Life intervention is a multicompo-
nent intervention promoting positive changes in daily sit-
ting and movement in office workers. SMART Work &
Life has been developed with input from office workers,
local council office workers, workplace champions, council
stakeholders, recently published research, experiences in
Australia (the Stand Up Australia programme of research
e.g., Stand Up Comcare and Stand Up Victoria) [30], and a
12-month RCT of a previous version of the intervention -
SMArT Work [24, 27, 31]. As a result, SMArT Work has
been refined and extended to become SMART Work &
Life. SMARTWork & Life incorporates improvements that
were noted following the SMArT Work RCT and ad-
dresses the gaps in existing interventions by going beyond
sitting in the workplace to also focus on behaviour change
outside of work, emphasising a novel ‘whole-of-day’ pre-
ventive approach to sitting reduction.
SMART Work & Life is grounded in several behaviour
change theories (Social Cognitive Theory [32], Organisa-
tional Development Theory [33], Habit Theory [34],
Self-Regulation Theory [35] and Relapse prevention The-
ory [36]) and implemented through the Behaviour Change
Wheel (BCW) and the associated COM-B approach
[37].The latter has ‘capability’, ‘opportunity’, and ‘motiv-
ation’ as central components in guiding ‘behaviour’.
Intervention goal
The aim of the intervention will be to promote and main-
tain at least a 60 min per day reduction in daily sitting
time compared to usual practice at 24 months. Recent
experimental evidence has demonstrated a reduction in
glucose, insulin and blood pressure following regular
standing and walking breaks (i.e., every 20–30 min), with
total reductions in sitting varying from 28 min to 60 min
across the course of a day [12, 13, 15, 16, 18]. Further-
more, using statistical modelling we have observed that
interchanging 30 mins/day of sitting (measured with the
activPAL) with standing and stepping is associated with
favourable differences in insulin sensitivity [9] and inflam-
mation [10]. In a similar analysis, interchanging 2 h of sit-
ting/day with standing or stepping was associated with
favourable differences in glucose, triglycerides, cholesterol
and waist circumference [11]. Others have also shown that
each additional hour/day of sitting past 7 h and 8 h is
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associated with a 5 and 4% higher risk of all-cause mortal-
ity in the general population [38, 39]. Thus based on the
available evidence, a reduction in sitting time of 60 min per
day is likely to represent a clinically meaningful difference
in behaviour.
Main intervention components
Organisational strategies grounded in Social Cognitive
Theory and Organisational Development Theory (target-
ing ‘opportunity’ & ‘motivation’ through BCW interven-
tion functions: enablement, persuasion, environmental
restructuring, modelling, positive emotion): 1) we will
seek buy-in from the management through the briefing
events by explaining the importance of reducing and
breaking up sitting at work and how this may lead to
workplace benefits without negatively affecting perform-
ance and productivity; 2) a brief awareness session (on-
line/video) will reinforce the benefits for the workforce
and employers of reducing sitting time in and outside of
work and encourage them to brainstorm organisational
strategies that could take place, review any current pol-
icies around being active at work as well as create new
policies around topics such as standing and walking
meetings, provision for lunch time walking, internal
competitions and displaying signs around the workplace.
We will also encourage managers to review the layout of
their office space to promote increased movement of
staff e.g., location of printers, waste bins, water coolers;
3) Modelling of the positive behaviour from managers
will also be emphasised.
Environmental strategies grounded in Social Cognitive
Theory, Organisational Development Theory and Habit
Theory (targeting ‘capability’, ‘motivation’ & ‘opportunity’
through BCW intervention functions: environmental re-
structuring, enablement as well as ‘automatic’ forms of
motivation, including emotion): 1) Small-scale environ-
mental restructuring in the office and at home (e.g., re-
location of printers and waste bins), 2) Motivational and
reminder signs around the office space and at home to sit
less and move more, 3) A height-adjustable workstation to
allow the individual to sit or stand to work. The individual
will get a choice of desk platform within a set budget. This
allows flexibility for office set up, participant preference
and avoids testing the effectiveness of a specific type of
desk rather than the concept.
Individual and group strategies grounded in Social
Cognitive Theory, Self-Regulation Theory and Relapse
Prevention Theory (targeting ‘capability, ‘motivation’ & ‘op-
portunity’ through BCW intervention functions: enable-
ment, persuasion, education and training): 1) An initial
online education session which covers health consequences
of sitting and benefits of reducing and regularly breaking
up sitting. The session encourages participants to estimate
their own sitting time, brainstorm strategies to reduce
sitting at work and outside of work, consider barriers to re-
ducing and breaking up sitting and ways to overcome these
barriers. At the end of the session individuals will be en-
couraged to set a goal around sitting less and an action
plan to achieve this. The focus on overall daily sitting will
be emphasised rather than just workplace sitting; 2)
Self-monitoring of sitting behaviour across the whole
waking day will be encouraged through the use of free
computer prompts, timers and mobile phone apps. For ex-
ample, the Rise & Recharge app. The importance of
self-monitoring and prompts will be introduced during the
education session and the choice of apps, computer soft-
ware and prompts will be presented during the session; 3)
Workplace champions will receive training to encourage
their colleagues, deliver brief group coaching, implement
competitions and send emails. The coaching sessions will
be used to discuss progress, review goals and action plans,
discuss personal or social barriers and any benefits experi-
enced. These coaching sessions will take place four times
during the intervention period; 4) Workplace champions
will send out monthly motivational/education emails; 5)
Social support, from colleagues and family members, will
be encouraged through regular activity competitions inside
and outside of work.
Intervention arms 1 and 2
Both intervention arms will receive all of the intervention
components listed in the previous sections. However,
intervention arm 2 will not receive a height-adjustable
workstation. By having both intervention arms receive the
same intervention with the exception of the workstation
will allow us to investigate how important providing this
component is for reducing sitting.
Control arm
Office clusters assigned to the usual practice control
arm will be asked to continue with their usual occupa-
tional health promotion conditions. Participants in the
control arm will be asked to complete the same study
measurements as those in the intervention arms, at the
same time points.
Measurements
The outcome measurements (unless stated otherwise) will
be assessed at four time points; baseline and 3, 12 and
24 months following baseline by a team of researchers
who have undergone relevant training. At the baseline
visit, the study will be fully explained to the participant
again and written informed consent will be obtained if the
participant is happy to take part in the study. The consent
procedure will be performed by a researcher with appro-
priate consent training. Only once informed consent has
been given will measurements be taken.
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Objectively measured sitting and physical activity
The activPAL™ micro device will be worn on the thigh
24 h/day for 7 days. It will be made waterproof using a ni-
trile sleeve and waterproof medical dressing. This device
will assess a variety of aspects of behaviour including sit-
ting, standing and stepping time (total and light and
moderate-to-vigorous), prolonged sitting and standing,
number of steps and number of transitions from sitting to
an upright posture. These variables will be calculated daily
(i.e., across all waking hours) and during work hours only.
Participants who provide an adequate number of valid days
will receive a £10 voucher at the end of each data collection
time point. The activPAL is commonly used in sedentary
behaviour and physical activity research [40] and has been
found to be a valid and reliable measure of sitting, standing,
stepping and postural transitions in adults [41–43]. The
activPAL data will be cleaned and processed using a previ-
ously published automated algorithm [44].
A wrist-worn accelerometer will also be worn on the
non-dominant wrist 24 h/day for 7 days. Time spent in
different intensities of physical activity as well as sleep
duration and other sleep variables such as efficiency will
be calculated.
Participants will be asked to complete a short log each
day to note the time they went to bed, went to sleep,
woke up and got out of bed each day, work times, as
well as recording any periods throughout the day if they
removed the devices.
Self-reported lifestyle behaviours
Participants will be asked to complete an adapted ver-
sion of the Occupational Sitting and Physical Activity
Questionnaire [45], an adapted version of the past day
recall of sedentary time questionnaire, which asks about
sitting outside of work in certain contexts [46], as well
as estimate the hours they spend sitting and breaking up
sitting as part of their job [47]. Participants will be asked
to estimate the percentage of their working day that they
spend at their desk space and their office space.
Dietary behaviours and alcohol intake will be assessed
using questions from the Whitehall II study [48]. Infor-
mation on smoking status (current smoker, past smoker,
non-smoker) will also be gathered by self-report.
Self-report sleep duration and quality will be assessed
using the Pittsburgh Sleep Quality Index [49].
Demographic, medical history and medication
During their baseline visit, participants will be asked their
age and date of birth, ethnicity, education level, current
job role and pay grade, working site, working hours,
length of time in post, number of people in their office
and department, postcode and household composition. At
each follow up visit, participants will be asked if there has
been any change in these aspects.
Details of any history of disease or injuries that may
indicate an inability to participate in the study will be
measured. If needed, results will be reviewed to define
eligibility. Medication will also be recorded.
Anthropometrics and blood pressure
Height will be measured in centimetres (cm), to 1 decimal
place, using a Leicester portable height measure. Waist
circumference will be measured using a standard an-
thropometric tape measure, with the tape measure being
placed around the abdomen midway between the upper-
most border of the iliac crest and the lower edge of the
chest (thorax) formed by the bottom edge of the rib cage.
A reading in cm, to 1 decimal point, will be taken when
the tape is snug, but not compressing the skin. Weight, in
kilograms (kg), and body composition will be measured
using a Body Composition Analyser. Participants will re-
move shoes, socks and heavy outerwear clothing and en-
sure their pockets are empty before stepping on to the
scales. Body mass index (BMI) is calculated by the scales
as kg/m2. Blood pressure (BP) will be assessed using an
Omron automated blood pressure monitor (Omron
Healthcare Europe). Participants will be asked to sit
quietly and relax prior to having their BP measurements
taken and three readings will be taken, with the average of
the last two readings used in the analyses.
Biochemical assessments
The Quo-Test® HbA1c Analyser (point-of-care device;
EKF Diagnostics, Cardiff, UK) will be used to measure
glycated haemoglobin. Additionally, we will use the Car-
diochek® PLUS point-of-care analyser (PTS Diagnostics,
IN, USA) to measure circulating cholesterol (total, HDL,
LDL), triglycerides and glucose. Capillary blood samples
will be taken from each participant using the finger prick
method. The CardioChek® PLUS system, which is a port-
able hand-held device that requires between 15 and
40 μL (millions per microliter) of blood taken using a
finger-stick, will be used for these measurements. No
blood will be stored and all blood contaminated testing
sticks will be deposed of appropriately. Participants will
be asked to fast (no food or drink except water) for at
least 10 h prior to the blood tests. All participants will
receive feedback on these results.
Work-related measures
Job performance [50] and job satisfaction [51] will be
measured using single-item 7-point likert scales. Work
engagement (characterized by vigour, dedication, and ab-
sorption) will be measured using the Utrecht Work En-
gagement Scale [52]; a multi-item 7-point likert scale.
The Need for Recovery Scale [53] will be used to meas-
ure occupational fatigue. Musculoskeletal symptoms will
be assessed using the Standardised Nordic Questionnaire
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[54]. Work load and relations will be assessed using the
demands, control and support scales from the Health
and Safety Executive Management Standards Indicator
Tool using a 5-point likert scale [55]. Sickness present-
eeism will be assessed by the validated 8-item Work
Limitations Questionnaire [56] which asks participants
to rate on a six-point Likert scale how their health has
affected aspects of their work in the past 2 weeks. Data
on sickness absence will be collected using both
self-report and from employer records and include fre-
quency and duration of self-certified and certified sick-
ness. Reasons for sickness absence will also be recorded.
Data on sickness absence will be collected for 12 months
prior to the intervention and for the 24 months of the
intervention period.
Social norms, cohesion, support and strategies for sitting less
Organisational social norms will be assessed using eight
items (e.g., ‘My workplace is committed to supporting staff
choices to stand or move more at work’) on a 5-point
Likert [25]. To capture the presence and extent of cohe-
sion, cooperation and community in workplace teams the
‘social community’ sub-scale of the Copenhagen Psycho-
social Questionnaire-II [57] will be used. This sub-scale
uses three 6-point Likert scale items. Participants will be
asked about the support they have received from the or-
ganisation, manager, colleagues and family for sitting less
and moving more often [58]. Participants will be asked to
report the frequency of any strategies they have used to sit
less and move more often [58].
Mental health, well-being and quality of life
Health-related quality of life will be assessed using the
EQ5D-5 L [59]. Anxiety and depression will be mea-
sured using the Hospital Anxiety and Depression Scale
[60]. Stress will be measured using the Perceived Stress
Scale [61]. Emotion will be assed using the Positive and
Negative Affect Schedule which comprises two mood
scales (positive and negative) [62]. Wellbeing will be
measured using the World Health Organisation-Five
Well-Being Index (WHO-5) [63].
Physical and mental fatigue
The Fatigue Scale [64] will be used to measure fatigue
severity. The Fatigue Scale is one of the most widely
used measures assessing fatigue and includes 11 items,
seven assessing physical fatigue and four assessing men-
tal fatigue. Responses to items are measured using a
4-point Likert-scale.
Health-related resource use
The health-related resource use will be based on a vari-
ant of the Client Service Receipt Inventory [65] and will
include services that this population are likely to utilise
such as GPs and Practise nurse appointments, occupa-
tional health visitors and other professionals that are
deemed appropriate.
Workplace and workplace champion characteristics
At baseline each cluster will be asked to complete a
short audit of their work environment. Basic information
about each workplace champion in the intervention
clusters will be collected at baseline e.g., gender, age, job
role, length of experience being a workplace champion.
Process evaluation
The process evaluation methods will be a mix of ques-
tionnaires, interviews, focus groups and direct observa-
tion. The process evaluation will be used to understand:
the participants’ experiences of the intervention and its
different components; any discrepancies between ex-
pected and observed outcomes; the influence of inter-
vention components and context on the observed
outcomes; sustainability; the extent of any contamination
between intervention and control; and, any unexpected
events arising from participation. Completion of education
and attendance at coaching sessions will be recorded.
Self-report questionnaires provided to study participants
will evaluate their opinions of the various intervention
components (e.g. education, coaching, self-monitoring,
workstation). Interviews and focus groups with study par-
ticipants (sub-sample) will further examine engagement in
the various components of the intervention, along with any
barriers or facilitators to participating in the various com-
ponents. Focus groups with workplace champions will fur-
ther examine the intervention implementation and the
champions’ experiences of delivery. All interviews and focus
groups will be audio-recorded and transcribed verbatim.
Throughout the intervention we will monitor the fidel-
ity of the intervention implementation using the Nor-
malisation Process Theory framework [66] in line with
guidance from the National Institutes of Health Behav-
iour Change Consortium and the DESMOND collabora-
tive. Observations or recordings (via voice recorder) of
sessions (e.g., coaching) will take place in both interven-
tion arms to assess whether the content was delivered as
expected and receipt of the intervention by attendees.
During the observations a case report form will also be
completed. The case report form will combine an ‘adher-
ence measure’ to capture delivery (mode of delivery
(dose)/duration/content) and use of resources (mate-
rials/activities). The structured observation tool will as-
sess facilitator delivery of prescribed behaviours and
behaviour change techniques. The case report form will
also contain specific objective ‘receipt’ measures and will
likely include examples related to how well the partici-
pants understand the content and engage in the session.
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Observations in the office clusters will also take place in
a random sample of offices in both intervention arms at
several time points during the intervention period. Each
observation will be performed over one whole working
day. This observation work will be guided by the four do-
mains of the Normalisation Process Theory and an obser-
vation guide will highlight the types of behaviours of focus,
such as: use of height adjustable workstation, sitting and
standing time, engagement with colleagues, walking/stand-
ing meetings as well as office structure, posters displayed.
Practically, the observation work will include keeping
structured field notes and collating relevant documentation
for further context and insight, and may include informal
discussions with office workers and workplace champions.
A random sample of control offices will also be observed
to judge contamination and other practices that may im-
pact on our behaviours of interest.
Statistical analysis
Primary and secondary outcomes
The aim of the primary analysis is to investigate the im-
pact of the multi-component intervention (SMART
Work & Life), with and without a height-adjustable
workstation, on objectively measured daily sitting time
compared to usual practice at 24-month follow-up. The
primary outcome analysis is powered to detect a signifi-
cant difference in sitting time of 60 min/day at
24 months. However, discontinuation of the study due
to futility will be considered in a formal interim analysis
at 12 months. An Independent Data Monitoring Com-
mittee (DMC) will be convened to review the primary
outcome at 12 months. The conditional probability of
the final study results being statistically significant given
the data observed at 12 months will be calculated and
the DMC will make a recommendation based on this
and other important factors (i.e. trial conduct, data qual-
ity, participant retention) of whether or not to continue
follow-up until 24 months. If the DMC decide the data
from the interim analysis at 12 months provides satisfac-
tory evidence to continue, the trial will continue to
follow-up participants to 24 months. Furthermore, only
if both arms are determined to be futile at the interim
analysis stage will the trial be stopped early.
The primary analysis will be performed using a linear
multilevel model with sitting time as the outcome variable.
Levels to indicate the clustering of workers within office
sites, a categorical variable for randomisation group as the
explanatory variable (control will be the reference group
and will be compared to intervention 1 and intervention
2), and terms for the stratification factors (area and cluster
size), baseline values and device wear time will be con-
founders. In these linear multilevel models, office clusters
will be incorporated as a random effect to model worker
heterogeneity within office sites. The structure of the
variance-covariance matrix for the random effect will be
assumed to be unstructured and the models will be esti-
mated using restricted maximum likelihood. For the pri-
mary analysis, missing data will not be replaced (complete
case analysis) and participants will be included in the
intervention group in which their clusters were rando-
mised irrespective of the intervention that was actually
received.
The baseline characteristics of those who have complete
primary outcome data will be compared with those who
dropped out from the study in order to investigate differ-
ences between them.
A sensitivity analysis using multiple imputation will be
performed to evaluate the impact of missing outcome data
on the results obtained and to account for uncertainty asso-
ciated with imputing data (full intention-to-treat analysis).
Missing data will be replaced using multiple imputation
methods in Stata using the MI command. The effect size
will also be estimated using a per-protocol analysis, which
will only include those who were compliant with the proto-
col and follow-up visits. Secondary outcomes, including
those measured at other time-points, will be analysed using
similar methodology. We will additionally assess data from
all time points for the primary outcome in a single analysis
using repeated measured. We will also conduct a subgroup
analysis which compares the treatment effect in those clus-
ters in which other work place health initiatives were taking
place at the same time as the study compared to those
where there were no such initiatives.
All tests and reported p-values will be two-sided. Esti-
mates will be presented with 95% confidence intervals.
Process evaluation
Questionnaire data will be summarised using fre-
quency counts and means (± SD) where appropriate.
Audio-recordings of interviews and focus groups
with office workers and workplace champions will be
transcribed verbatim and analysed using framework
analysis using the Normalisation Process Theory as
the overarching framework.
Cost effectiveness
The economic evaluation will consist of two analyses. i) a
cost-consequence analysis based on the observed results
within the trial period and ii) a cost-effectiveness analysis
where differences between groups in the trial will be ex-
trapolated to the longer term where appropriate.
For both analyses, costs in both arms will be estimated
from a National Health Service (NHS) and Personal Social
Services (PSS) perspective (consistent with that used by
the National Institute for Health and Care Excellence
(NICE)) as well as a wider public sector perspective. In
each analysis, the cost of the SMART Work & Life groups
will include an estimate of the cost of the intervention,
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with and without the height adjustable desk. The cost of
the intervention consists of the cost of equipment (such
as desks) and the cost of training and delivery of interven-
tion. We will estimate the cost of the equipment from
manufacturer’s estimates of costs. We will also estimate
the cost of training and delivery of intervention by the
workplace champions.
Within-trial analysis Within the period of the trial, we
will collect resource use estimates from participant ques-
tionnaires. These questionnaires will record health re-
lated resource use as well as absence from employment.
The health related resource use will be based on a vari-
ant of the Client Service Receipt Inventory and will in-
clude services that this population are likely to utilise
such as GPs and Practice nurse appointments, occupa-
tional health visitors and other professionals that are
deemed appropriate. Costs of resources will be calcu-
lated by applying published national unit cost estimates
(e.g. NHS reference costs or Personal Social Services Re-
search Unit costs of health and social care), where avail-
able, to estimates of relevant resource use.
A range of outcomes will be assessed in the trial in-
cluding health related quality of life, measured using the
EQ5D-5 L The within trial analysis will present incre-
mental results for the primary and secondary outcomes
(including EQ5D) in both intervention and control arms
and will be compared with the incremental costs mea-
sured above. We will also present the results in terms of
the differences in time absent from work between the
groups. As there is some controversy over inclusion of
productivity losses in the assessment of cost-effectiveness,
the within trial analysis will be presented both with and
without estimates of the cost of sickness absenteeism. This
will allow decision makers to assess the importance of in-
clusion of absenteeism costs when deciding whether to
implement the intervention.
Longer term analysis While there may be short term
health benefits from reducing levels of sitting time, the
longer term effects on mortality on office workers is
likely to be more important. We will therefore use exist-
ing evidence that links short-term trial endpoints and
longer term outcomes. While some existing evidence
used covariates to adjust for confounding factors, it is
not possible to assess unmeasured confounders. There-
fore, we will use existing evidence to extrapolate costs
and effects to a more appropriate time horizon; however,
as recommended by Taylor and Elston [67] we will ex-
plain how the surrogate-final outcomes relationship is
quantified and explore the uncertainty around the use of
the surrogate outcome (in this case sitting time) through
sensitivity analysis.
If appropriate an Incremental Cost-effectiveness Ratio
for the extrapolated period will be reported using the Qual-
ity Adjusted Life Year (QALY). As with the within-trial
analysis, we will conduct analyses where productivity losses
are included/excluded to assess the impact on decision
making. Costs and effects will be discounted at the prevail-
ing recommended rate (currently 1.5% per annum on both
costs and effects), but will be the subject of sensitivity ana-
lysis to reflect the ongoing uncertainty around appropriate
discount rates for public health interventions. We will con-
duct probabilistic sensitivity analyses to allow a character-
isation of the uncertainty around the adoption decision
which we will depict using cost-effectiveness acceptability
curves. Sensitivity analyses will be performed to determine
the robustness of the results to altering certain assump-
tions such as the discount rate, inclusion/exclusion of
productivity losses and the robustness of the relationship
between sitting time and mortality.
Data handling
All data collected will be kept strictly confidential and in
accordance with all relevant legislation. The participants
will be identified on documentation by a unique ID num-
ber, not by name (apart from on the consent form and en-
rolment log). All research data will be kept in a secure
location within University of Leicester, University of Sal-
ford or the University Hospitals of Leicester, accessible
only by named members of the research team during the
active phase of the study and until the data have been ana-
lysed. It will then be archived in line with University of
Leicester policy. The Leicester Clinical Trials Unit will be
providing a Good Clinical Practice compliant database so-
lution using a Clinical Data Management System called
InferMed Macro. This is a secure and validated database
solution with quality control mechanisms to ensure that
the data collected are complete and accurate.
Discussion
Office workers exhibit high levels of sitting both inside
and outside of work [7, 8], with accumulating evidence
demonstrating the detrimental impacts of high levels of
sedentary behaviour on health [3–6] interventions in this
population are needed. Although previous workplace in-
terventions have shown promise in reducing sitting time
[22, 23] study designs have been of low quality [22, 23],
with only a handful of fully powered cluster randomised
controlled trials being conducted [24, 25].
Strengths of this study include the robust randomised
controlled trial design, with randomisation at the cluster
level to reduce contamination, the large fully powered sam-
ple, the inclusion of short, medium and longer term follow
up measures, the extensive quantitative and qualitative
process evaluation, the rigorous economic evaluation and
the use of an objective measure of physical activity as the
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primary outcome. Furthermore, this study is unique, in
that it will be delivered at two levels i.e., with and without
the provision of a height-adjustable workstation. These
study aspects will all contribute to building the evidence
base around the effectiveness of interventions to reduce sit-
ting time and inform policy guidelines for population and
workplace health and wellbeing.
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